The short version of GHS-R1a fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-07-14 and is reviewed periodically as new material appears.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
== Alternative nomenclature == Some of the metabolites in glycolysis have alternative names and nomenclature. In part, this is because some of them are common to other pathways, such as the Calvin cycle.
=== Extraction === The recognised metalloids can be obtained by chemical reduction of either their oxides or their sulfides. Simpler or more complex extraction methods may be employed depending on the starting form and economic factors. Boron is routinely obtained by reducing the trioxide with magnesium: B2O3 + 3 Mg → 2 B + 3MgO; after secondary processing the resulting brown powder has a purity of up to 97%. Boron of higher purity (> 99%) is prepared by heating volatile boron compounds, such as BCl3 or BBr3, either in a hydrogen atmosphere (2 BX3 + 3 H2 → 2 B + 6 HX) or to the point of thermal decomposition. Silicon and germanium are obtained from their oxides by heating the oxide with carbon or hydrogen: SiO2 + C → Si + CO2; GeO2 + 2 H2 → Ge + 2 H2O. Arsenic is isolated from its pyrite (FeAsS) or arsenical pyrite (FeAs2) by heating; alternatively, it can be obtained from its oxide by reduction with carbon: 2 As2O3 + 3 C → 2 As + 3 CO2. Antimony is derived from its sulfide by reduction with iron: Sb2S3 → 2 Sb + 3 FeS. Tellurium is prepared from its oxide by dissolving it in aqueous NaOH, yielding tellurite, then by electrolytic reduction: TeO2 + 2 NaOH → Na2TeO3 + H2O; Na2TeO3 + H2O → Te + 2 NaOH + O2. Another option is reduction of the oxide by roasting with carbon: TeO2 + C → Te + CO2. Production methods for the elements less frequently recognised as metalloids involve natural processing, electrolytic or chemical reduction, or irradiation. Carbon (as graphite) occurs naturally and is extracted by crushing the parent rock and floating the lighter graphite to the surface.
== Causes of reduced IGF1 levels == Metabolic dysfunction–associated steatotic liver disease, especially at advanced stages of steatohepatitis and fibrosis Oral estrogens suppress growth hormone-induced IGF1 production in the liver by antagonism of growth hormone receptors.
Sources: en.wikipedia.org
In times of severe political confrontation and radical economic change, members of Mikołajczyk's agrarian movement (the Polish People's Party) attempted to preserve the existing aspects of mixed economy and protect property and other rights. However, after the 1947 elections, the Government of National Unity ceased to exist and the communists moved towards abolishing the post-war partially pluralistic "people's democracy" and replacing it with a state socialist system. The communist-dominated front Democratic Bloc of the 1947 elections, turned into the Front of National Unity in 1952, became officially the source of governmental authority. The Polish government-in-exile, lacking international recognition, remained in continuous existence until 1990.
In the early 2000s, White Castle tried expanding into the Kansas City market, with at least one location in Kansas, but those restaurants were closed several years later. In April 2020, White Castle responded to the COVID-19 pandemic by announcing that the chain would be delivering free meals to healthcare workers. White Castle also offered a free dessert in the month of May 2021 to anyone who showed a vaccination certificate. In certain regions, White Castle offered four hours of paid time off for workers who get both doses of an eligible COVID-19 vaccination and present their vaccination certificate to management.
=== Development === The first human clinical trial using ex vivo dendritic cells transfected with mRNA encoding tumor antigens (therapeutic cancer mRNA vaccine) was started in 2001. Four years later, the successful use of modified nucleosides as a method to transport mRNA inside cells without setting off the body's defense system was reported. Clinical trial results of an mRNA vaccine directly injected into the body against cancer cells were reported in 2008. BioNTech in 2008, and Moderna in 2010, were founded to develop mRNA biotechnologies. The US research agency DARPA launched at this time the biotechnology research program ADEPT to develop emerging technologies for the US military. The agency recognized the potential of nucleic acid technology for defense against pandemics and began to invest in the field. DARPA grants were seen as a vote of confidence that in turn encouraged other government agencies and private investors to invest in mRNA technology. DARPA awarded at the time a $25 million grant to Moderna. The first human clinical trials using an mRNA vaccine against an infectious agent (rabies) began in 2013. Over the next few years, clinical trials of mRNA vaccines for a number of other viruses were started. mRNA vaccines for human use were studied for infectious agents such as influenza, Zika virus, cytomegalovirus, and Chikungunya virus.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
The standard approach is reversed-phase high-performance liquid chromatography, with purity reported as the relative area of the main peak. Ultraviolet detection near 214 nanometers is typical for peptides. Mass spectrometry is added to confirm identity rather than to quantify purity.